All the news Showing 10 of 27 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources 'Another swing, another miss' for Gilead as NASH combo flops in phase 2 Fierce Biotech / 16 December 2019 Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Gilead press release / 16 December 2019 Fatty livers halt tumor-suppressing protein, increasing cancer risk Fierce Biotech / 21 October 2019 Obesity epidemic results in Non-Alcoholic Fatty Liver Disease (NAFLD) becoming the most common cause of liver disease in Europe EASL / 26 September 2019 Why fatty liver disease could be the next public health crisis Daily Telegraph / 25 September 2019 Gilead experimental NASH drug fails another study Reuters / 29 April 2019 Hepatic Steatosis Highly Prevalent in Young Adults With Lifelong HIV Infectious Disease Advisor / 17 April 2019 Experts warn of fatty liver disease 'epidemic' in young people The Guardian / 12 April 2019 Second-generation thiazolidinedione, MSDC-0602K may significantly improve liver enzymes, fibrosis, and glycaemic markers with minimal adverse events, according to a Phase 2b study EASL / 12 April 2019 With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition STAT / 19 February 2019 ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds